- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT01172899
Bariatric Surgery in Children. (BASIC)
The BASIC Trial. Morbid Obesity in Children and Adolescents: a Prospective Randomised Trial of Conservative Treatment Versus Surgery
Rationale:
In the Western world overweight and obesity is an increasing problem both in adults and in children. In youth, it is associated with early death and a number of co-morbidities including metabolic and endocrine changes, increased inflammatory status, cardiovascular abnormalities, nonalcoholic fatty liver disease, and impaired quality of life.
The standard treatment for morbid obesity in children is by combined life style interventions. However, the medium and long term effects of dietetic interventions, behaviour therapy and medication is relatively poor. In adults bariatric surgery shows good results with up to 30% weight reduction in 3 years. The preliminary results in youth are similar, but surgery in this age group is relatively uncommon. In the Netherlands surgery in this age group is only allowed in clinical trials, until the benefits and risks have been established. (National Health Authorities)
Objective:
To determine if surgery gives a superior weight and body mass index (BMI) reduction than combined life style interventions in adolescents with morbid obesity and to assess its effect on obesity associated co-morbidity.
Study design:
Prospective randomised interventional study.
Study population:
Morbidly obese children, aged 14 - 16 years, with sex and age adjusted BMI >40 kg/m2 or >35 kg/m2 with co-morbidity.
Intervention:
Bariatric surgery by laparoscopic adjustable gastric band (LAGB) or combined life style interventions
Main study parameters/endpoints:
Primary endpoints: weight loss, loss of excess weight, loss of excess BMI. Secondary endpoints: Body composition, pubertal development, metabolic and endocrine changes, inflammatory status, cardiovascular abnormalities, non-alcoholic steatohepatitis, brain development, quality of life, and behaviour changes. The potential complications of surgery are monitored.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Limburg
-
Maastricht, Limburg, Holanda, 6202ZA
- Maastricht University Medical Center
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Aged 14 to 16
Age and sex adjusted BMI >40 kg/m2 or >35 kg/m2 with associated co-morbidity.
* Associated co-morbidity includes: glucose intolerance, type 2 diabetes, hypertension, pseudotumor cerebri, acanthosis nigricans, obstructive sleep apnoea syndrome, depression, arthropathies, non-alcoholic steatohepatitis and dyslipidemia.
- > 1 year multidisciplinary organized weight reducing attempts with less than 5% weight loss
- Demonstrate decisional capacity
Exclusion Criteria:
- Psychologically not suitable
- Pre-menarche or bone age <15 years in boys
- Obesity associated to other disorders such as hypothyroidism
- Syndromal disorders such as Prader-Willi syndrome
- Severe cardiorespiratory impairment (ASA class 3 or higher)
- Insufficiently fluid in the Dutch language
- Unwillingness to adhere to follow-up programmes
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: Grupo de controle
|
Control group will receive standard therapy consisting of combined lifestyle interventions.
|
|
Experimental: Laparoscopic adjustable gastric band
|
Laparoscopic gastric band placement.
Combined lifestyle interventions will continue after surgery.
Control group will receive standard therapy consisting of combined lifestyle interventions.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Weight
Prazo: 6 months
|
Weight loss, excess weight loss and loss of excess BMI.
|
6 months
|
|
Weight
Prazo: 12 months
|
Weight loss, excess weight loss and loss of excess BMI.
|
12 months
|
|
Weight
Prazo: 24 months
|
Weight loss, excess weight loss and loss of excess BMI.
|
24 months
|
|
Weight
Prazo: 36 months
|
Weight loss, excess weight loss and loss of excess BMI.
|
36 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Body composition
Prazo: 12 months
|
Next to anthropometric measurements, bone mineral content, bone density, lean bodymass and fat percentage will be assessed.
|
12 months
|
|
Pubertal development
Prazo: 6 months
|
Follow-up of hormonal status and Tanner stages.
|
6 months
|
|
Metabolic and endocrine changes
Prazo: 6 months
|
6 months
|
|
|
Inflammatory status
Prazo: 6 months
|
Measurement of serum inflammatory markers.
|
6 months
|
|
Cardiovascular abnormalities
Prazo: 6 months
|
6 months
|
|
|
Non-alcoholic fatty liver disease
Prazo: 6 months
|
Next to an ultrasound of the liver, serum levels of ALT, AST, ALP and GGT are measured.
CCL-2 is used as a surrogate marker to assess liver disease.
|
6 months
|
|
Quality of life changes
Prazo: 6 months
|
6 months
|
|
|
Behaviour changes
Prazo: 6 months
|
Measuring impulsivity and positive reward dominance with a computer task.
|
6 months
|
|
Operative complications
Prazo: up to 36 months
|
Early and late complications are being monitored
|
up to 36 months
|
|
Effects on sleep architecture
Prazo: 6 months
|
6 months
|
|
|
Brain development
Prazo: 6 months
|
If extra sponsorship can be gained, we will use fMRI and MEG in a subgroup to measure blood oxygen level-dependent (BOLD) brain response to food stimuli.
|
6 months
|
|
Body composition
Prazo: 24 months
|
Next to anthropometric measurements, bone mineral content, bone density, lean bodymass and fat percentage will be assessed.
|
24 months
|
|
Body composition
Prazo: 36 months
|
Next to anthropometric measurements, bone mineral content, bone density, lean bodymass and fat percentage will be assessed.
|
36 months
|
|
Pubertal development
Prazo: 12 months
|
Follow-up of hormonal status and Tanner stages.
|
12 months
|
|
Pubertal development
Prazo: 24 months
|
Follow-up of hormonal status and Tanner stages.
|
24 months
|
|
Pubertal development
Prazo: 36 months
|
Follow-up of hormonal status and Tanner stages.
|
36 months
|
|
Metabolic and endocrine changes
Prazo: 12 months
|
12 months
|
|
|
Metabolic and endocrine changes
Prazo: 24 months
|
24 months
|
|
|
Metabolic and endocrine changes
Prazo: 36 months
|
36 months
|
|
|
Inflammatory status
Prazo: 12 months
|
Measurement of serum inflammatory markers.
|
12 months
|
|
Inflammatory status
Prazo: 24 months
|
Measurement of serum inflammatory markers.
|
24 months
|
|
Inflammatory status
Prazo: 36 months
|
Measurement of serum inflammatory markers.
|
36 months
|
|
Cardiovascular abnormalities
Prazo: 12 months
|
12 months
|
|
|
Cardiovascular abnormalities
Prazo: 24 months
|
24 months
|
|
|
Cardiovascular abnormalities
Prazo: 36 months
|
36 months
|
|
|
Non-alcoholic fatty liver disease
Prazo: 12 months
|
Next to an ultrasound of the liver, serum levels of ALT, AST, ALP and GGT are measured.
CCL-2 is used as a surrogate marker to assess liver disease.
|
12 months
|
|
Non-alcoholic fatty liver disease
Prazo: 24 months
|
Next to an ultrasound of the liver, serum levels of ALT, AST, ALP and GGT are measured.
CCL-2 is used as a surrogate marker to assess liver disease.
|
24 months
|
|
Non-alcoholic fatty liver disease
Prazo: 36 months
|
Next to an ultrasound of the liver, serum levels of ALT, AST, ALP and GGT are measured.
CCL-2 is used as a surrogate marker to assess liver disease.
|
36 months
|
|
Quality of life changes
Prazo: 12 months
|
12 months
|
|
|
Quality of life changes
Prazo: 24 months
|
24 months
|
|
|
Quality of life changes
Prazo: 36 months
|
36 months
|
|
|
Effects on sleep architecture
Prazo: 12 months
|
12 months
|
|
|
Effects on sleep architecture
Prazo: 24 months
|
24 months
|
|
|
Effects on sleep architecture
Prazo: 36 months
|
36 months
|
|
|
Behaviour changes
Prazo: 12 months
|
Measuring impulsivity and positive reward dominance with a computer task.
|
12 months
|
|
Behaviour changes
Prazo: 24 months
|
Measuring impulsivity and positive reward dominance with a computer task.
|
24 months
|
|
Behaviour changes
Prazo: 36 months
|
Measuring impulsivity and positive reward dominance with a computer task.
|
36 months
|
|
Brain development
Prazo: 12 months
|
If extra sponsorship can be gained, we will use fMRI and MEG in a subgroup to measure blood oxygen level-dependent (BOLD) brain response to food stimuli.
|
12 months
|
|
Brain development
Prazo: 24 months
|
If extra sponsorship can be gained, we will use fMRI and MEG in a subgroup to measure blood oxygen level-dependent (BOLD) brain response to food stimuli.
|
24 months
|
|
Brain development
Prazo: 36 months
|
If extra sponsorship can be gained, we will use fMRI and MEG in a subgroup to measure blood oxygen level-dependent (BOLD) brain response to food stimuli.
|
36 months
|
|
Physical activity
Prazo: 6 months
|
Assessment of physical activity using a questionnaire and an accelerometer.
|
6 months
|
|
Physical activity
Prazo: 12 months
|
Assessment of physical activity using a questionnaire and an accelerometer.
|
12 months
|
|
Physical activity
Prazo: 24
|
Assessment of physical activity using a questionnaire and an accelerometer.
|
24
|
|
Physical activity
Prazo: 36 months
|
Assessment of physical activity using a questionnaire and an accelerometer.
|
36 months
|
|
Behavior towards food
Prazo: 6 months
|
Behavior towards food is assessed by questionnaires and a computerized model for wanting and liking of food.
|
6 months
|
|
Behavior towards food
Prazo: 12 months
|
Behavior towards food is assessed by questionnaires and a computerized model for wanting and liking of food.
|
12 months
|
|
Behavior towards food
Prazo: 24 months
|
Behavior towards food is assessed by questionnaires and a computerized model for wanting and liking of food.
|
24 months
|
|
Behavior towards food
Prazo: 36 months
|
Behavior towards food is assessed by questionnaires and a computerized model for wanting and liking of food.
|
36 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: LWE van Heurn, Professor, Maastricht University Medical Center
- Investigador principal: Yvonne Roebroek, PhD Student, Maastricht University Medical Center
- Investigador principal: Givan F Paulus, PhD Student, Spaarne Gasthuis, Haarlem
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Antecipado)
Conclusão do estudo (Antecipado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- NL26279.068.09
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .